UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 19.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 119,052 shares of the company's stock after purchasing an additional 19,315 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.16% of SpringWorks Therapeutics worth $4,301,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. Los Angeles Capital Management LLC lifted its stake in SpringWorks Therapeutics by 30.8% in the fourth quarter. Los Angeles Capital Management LLC now owns 61,760 shares of the company's stock worth $2,231,000 after acquiring an additional 14,548 shares during the last quarter. Schroder Investment Management Group lifted its stake in SpringWorks Therapeutics by 93.6% in the fourth quarter. Schroder Investment Management Group now owns 168,209 shares of the company's stock worth $6,113,000 after acquiring an additional 81,314 shares during the last quarter. Vanguard Group Inc. lifted its stake in SpringWorks Therapeutics by 6.6% in the fourth quarter. Vanguard Group Inc. now owns 7,158,871 shares of the company's stock worth $258,650,000 after acquiring an additional 445,593 shares during the last quarter. BIT Capital GmbH lifted its stake in SpringWorks Therapeutics by 18.7% in the fourth quarter. BIT Capital GmbH now owns 53,539 shares of the company's stock worth $1,934,000 after acquiring an additional 8,429 shares during the last quarter. Finally, Platinum Investment Management Ltd. purchased a new position in SpringWorks Therapeutics in the fourth quarter worth approximately $1,694,000.
Wall Street Analysts Forecast Growth
SWTX has been the subject of a number of recent research reports. TD Cowen reiterated a "hold" rating and issued a $47.00 price target (down previously from $66.00) on shares of SpringWorks Therapeutics in a research note on Tuesday, April 29th. Cowen downgraded shares of SpringWorks Therapeutics to a "hold" rating in a research note on Tuesday, April 29th. Guggenheim reiterated a "neutral" rating and issued a $47.00 price target on shares of SpringWorks Therapeutics in a research note on Monday, May 12th. Evercore ISI downgraded shares of SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 28th. Finally, Barclays reiterated an "equal weight" rating and issued a $47.00 price target (down previously from $63.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Seven investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $52.57.
Read Our Latest Research Report on SpringWorks Therapeutics
SpringWorks Therapeutics Stock Performance
SWTX stock remained flat at $46.80 during midday trading on Friday. 3,119,418 shares of the company's stock were exchanged, compared to its average volume of 2,289,351. SpringWorks Therapeutics, Inc. has a 12 month low of $28.21 and a 12 month high of $62.00. The company's fifty day moving average price is $43.41 and its 200-day moving average price is $43.52. The company has a market capitalization of $3.53 billion, a P/E ratio of -13.45 and a beta of 0.77.
SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The company reported ($1.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. The company had revenue of $49.09 million for the quarter, compared to analyst estimates of $64.19 million. As a group, sell-side analysts predict that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current year.
SpringWorks Therapeutics Company Profile
(
Free Report)
SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
Featured Stories
Before you consider SpringWorks Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SpringWorks Therapeutics wasn't on the list.
While SpringWorks Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
